<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04663763</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-2020-336</org_study_id>
    <nct_id>NCT04663763</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Short-course Radiotherapy Followed by the Combination of Immunotherapy and Chemotherapy in Locally Advanced Rectal Cancer</brief_title>
  <official_title>The Combination of Neoadjuvant Short-course Radiotherapy and Immunotherapy in Locally Advanced Rectal Cancer：A Open-label Single-arm Phase II Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang Cancer Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single arm, open-label, prospective phase II clinical trial to evaluate the&#xD;
      combination of neoadjuvant short-course radiotherapy and immunotherapy (PD-1 antibody) for&#xD;
      patients with locally advanced rectal cancer (LARC). A total of 40 patients will be enrolled&#xD;
      in this trial to receive 5*5Gy short-course radiotherapy, followed by 4 cycles of CAPOX&#xD;
      chemotherapy and PD-1 antibody. Then they will receive the TME surgery and another 4 cycles&#xD;
      of CAPOX chemotherapy. There are two cohorts according to the microsatellite instability&#xD;
      status: (1) the micro-satellite stable (MSS) cohort（n=32), (2) the MSI-high cohort (n=8). The&#xD;
      primary end point is the rate of pathological complete response (pCR). The long-term&#xD;
      prognosis and adverse effects will also be evaluated and analyzed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pCR rate</measure>
    <time_frame>The TME surgery will be recommended at 1 week after the neoadjuvant therapy. The pCR rate is evaluated after surgery. Assessed up to 6 months</time_frame>
    <description>Pathologic complete response rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>3-year DFS</measure>
    <time_frame>Assessed up to 3 years</time_frame>
    <description>3-year disease free survival rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-year local recurrence rate</measure>
    <time_frame>Assessed up to 3 years</time_frame>
    <description>3-year local recurrence rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-year OS</measure>
    <time_frame>Assessed up to 3 years</time_frame>
    <description>3-year overall survival rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade 3-4 adverse effects rate</measure>
    <time_frame>Assessed up to 3 years</time_frame>
    <description>Radiotherapy, immunotherapy and chemotherapy related grade 3-4 adverse events rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical complications</measure>
    <time_frame>Assessed up to 3 years from the TME surgery</time_frame>
    <description>Type and Rate of surgical complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Scale</measure>
    <time_frame>Assessed up to 5 years</time_frame>
    <description>The Quality of Life Scale (QoLS, range 0-60) will be used to evaluate the quality of life. Higher scores mean the better quality of life</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Locally Advanced Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Neoadjuvant short-course radiotherapy+immunotherapy+chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A total of 40 patients receive 5*5Gy short-course radiotherapy, followed by 4 cycles of CAPOX chemotherapy and PD-1 antibody, finally receive the TME surgery and another 4 cycles of CAPOX chemotherapy.&#xD;
Interventions:&#xD;
Shor-course radiotherapy: 25Gy/5Fx;&#xD;
Induction immunotherapy: Sintilimab 200mg ivgtt d1 q3w x 4 cycles;&#xD;
Concurrent Chemotherapy: Oxaliplatin: 130mg/m2 d1 q3w + Capecitabine: 1000mg/m2 d1-14 q3w x 4 cycles;</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PD-1 antibody</intervention_name>
    <description>Sintilimab is a humanized IgG4 monoclonal antibody against the programmed death-1 (PD-1) receptor. Usage: 200mg ivgtt d1 q3w.</description>
    <arm_group_label>Neoadjuvant short-course radiotherapy+immunotherapy+chemotherapy</arm_group_label>
    <other_name>Sintilimab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Usage: 1000mg/m2 d1-14 q3w</description>
    <arm_group_label>Neoadjuvant short-course radiotherapy+immunotherapy+chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Usage: 130mg/m2 d1 q3w</description>
    <arm_group_label>Neoadjuvant short-course radiotherapy+immunotherapy+chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Pathological confirmed rectal adenocarcinoma and the distance from anal verge less&#xD;
             than 12 cm;&#xD;
&#xD;
             2. Clinical stage T3-4 and/or N+ (AJCC 8th);&#xD;
&#xD;
             3. No distant metastases;&#xD;
&#xD;
             4. Age 18-70 years old, female and male;&#xD;
&#xD;
             5. ECOG 0-1;&#xD;
&#xD;
             6. No previous chemotherapy, radiotherapy, immunotherapy or other anti-tumor&#xD;
             treatment;&#xD;
&#xD;
             7. Adequate organ function defined at baseline as:&#xD;
&#xD;
               1. ANC ≥1.5×109 /L，PLt ≥75×109 /L，Hb ≥90 g/L;&#xD;
&#xD;
               2. TBIL ≤1.5×ULN, ALT ≤2.5ULN, AST ≤2.5ULN, BUN and Cr ≤1×ULN or Ccr ≥50ml/min&#xD;
                  (Cockcroft-Gault formula);&#xD;
&#xD;
               3. INR ≤1.5×ULN or PT ≤1.5×ULN (If the patient is receiving anticoagulant therapy,&#xD;
                  PT should be within the intended use range of the anticoagulant drug);&#xD;
&#xD;
             8. With good compliance and no serious comorbidity;&#xD;
&#xD;
             9. Women of childbearing age must have taken reliable contraceptive measures or have a&#xD;
             pregnancy test (serum or urine) within 7 days prior to enrollment and the results are&#xD;
             negative;&#xD;
&#xD;
             10. Subject volunteers to join the study, sign the informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. History of other uncured malignancies within 5 years. Cured tumor with good&#xD;
             prognosis, such as skin basal cell carcinoma, cervical cancer and superficial bladder&#xD;
             cancer, will be excluded;&#xD;
&#xD;
             2. Have received surgery within 4 weeks before the enrollment;&#xD;
&#xD;
             3. History of obstruction within 6 months before the enrollment;&#xD;
&#xD;
             4. History of active autoimmune disease, interstitial lung disease, epilepsy and&#xD;
             dysphrenia;&#xD;
&#xD;
             5. With uncontrolled cardiovascular disease: active coronary heart disease; grade&#xD;
             III-IV cardiac insufficiency according to the NYHA criteria; and myocardial infarction&#xD;
             within 1 year;&#xD;
&#xD;
             6. With active infection or fever of &gt;38.5 ℃ with unknown cause (tumor-induced fever&#xD;
             judged could be enrolled);&#xD;
&#xD;
             7. DPD deficiency;&#xD;
&#xD;
             8. Allergic to any component of chemotherapy or immunotherapy;&#xD;
&#xD;
             9. With congenital or acquired immunodeficiency (such as those with HIV infection),&#xD;
             active hepatitis B or hepatitis C;&#xD;
&#xD;
             10. Usage of corticosteroids (prednison dose of &gt; 10 mg/day) or other&#xD;
             immunosuppressors for systemic treatment within the first 14 days of research;&#xD;
&#xD;
             11. Receive attenuated live vaccine within 4 weeks before the research;&#xD;
&#xD;
             12. Pregnant women or breast-feeding women;&#xD;
&#xD;
             13. With other factors that would force to terminate the clinical trial ahead of time,&#xD;
             such as the development of other severe comorbidity that required combined treatment,&#xD;
             and family or social factors affecting the safety of patients or experimental data&#xD;
             collection, as judged by the researchers.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuping Zhu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhejiang Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yuping Zhu, MD</last_name>
    <phone>86-0571-88128011</phone>
    <email>drzyp@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yibo Cai, MD</last_name>
    <phone>86-0571-88128011</phone>
    <email>caiyiyibo@zju.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>571</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yuping Zhu, MD</last_name>
      <phone>86-0571-88128011</phone>
      <email>drzyp@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Yibo Cai, MD</last_name>
      <phone>86-0571-88128011</phone>
      <email>caiyiyibo@zju.edu.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Zhuo Liu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yibo Cai, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 28, 2020</study_first_submitted>
  <study_first_submitted_qc>December 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2020</study_first_posted>
  <last_update_submitted>December 4, 2020</last_update_submitted>
  <last_update_submitted_qc>December 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neoadjuvant short-course radiotherapy</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Locally advanced rectal cancer</keyword>
  <keyword>Pathological complete response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

